• Home
  • Search Results
  • [Carcinogenicity of acrylonitrile and evaluation of approaches to pathogenetic correction of acrylate toxicity and antitumorigenic anthracycline doxorubicin toxicity during chemotherapy].

[Carcinogenicity of acrylonitrile and evaluation of approaches to pathogenetic correction of acrylate toxicity and antitumorigenic anthracycline doxorubicin toxicity during chemotherapy].

Vestnik Rossiiskoi akademii meditsinskikh nauk (2013-07-04)
M M Tarskikh, M A Shumbasov, S I Kolesnikov
ABSTRACT

Statistical analysis within the 20-year period showed that approximately 49% of workers who were exposed to widespread industrial poison acrylonitrile subsequently died from malignancy of different localization. The conducted experimental investigations demonstrated that acrylonitrile with the subacute intoxication of animals, the anti-tumor antibiotic doxorubicin, their combination, interwoven tumor and tumor developed against the background the introduction of acrylate and subsequent treatment doxorubicin led to onset of free-radical reactions. These reactions by themselves might stimulate development of malignancy. This fact confirms the need for antioxidant tracking of chemotherapy of tumors in the similar clinical cases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Acrylonitrile, ≥99%, contains 35-45 ppm monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Acrylonitrile, analytical standard
Sigma-Aldrich
Acrylonitrile, ≥99%, contains 35-45 ppm monomethyl ether hydroquinone as inhibitor
Supelco
Acrylonitrile solution, certified reference material, 5000 μg/mL in methanol